Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncodesign Precision MedicineXPAR:ALOPM 33 PS Ratio is 21.33 as of Jul. 17, 2026, which is 2% above its 10-year median of 20.94. GuruFocus rates XPAR:ALOPM with a GF Score™ of 33/100 and a GF Value™ of €0.29 (Fairly Valued). The stock has 1 warning sign investors should review. Among 930 Biotechnology companies, Oncodesign Precision Medicine ranks worse than 68.92% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Oncodesign Precision Medicine's share price is €0.32.
Oncodesign Precision Medicine's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.02. Hence, Oncodesign Precision Medicine's PS Ratio for today is 21.33.
Good Sign:
Oncodesign Precision Medicine SA stock PS Ratio (=24.5) is close to 1-year low of 23.93.
The historical rank and industry rank for Oncodesign Precision Medicine's PS Ratio or its related term are showing as below:
XPAR:ALOPM'
s PS Ratio Range Over the Past 10 Years
Min: 1.11 Med: 20.94 Max: 70.73
Current: 22.87
During the past 6 years, Oncodesign Precision Medicine's highest PS Ratio was 70.73. The lowest was 1.11. And the median was 20.94.
XPAR:ALOPM's PS Ratio is ranked worse than 68.92% of 930
companies
in the Biotechnology industry
Industry Median: 9.3
vs XPAR:ALOPM: 22.87
During the past 6 years, Oncodesign Precision Medicine's highest 3-Year average Revenue per Share Growth Rate was -53.70% per year. The lowest was -73.00% per year. And the median was -69.20% per year.
Back to Basics: PS Ratio
Oncodesign Precision Medicine (XPAR:ALOPM) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Oncodesign Precision Medicine PS Ratio Related Terms
Oncodesign Precision Medicine PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALOPM vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, Oncodesign Precision Medicine's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncodesign Precision Medicine PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's PS Ratio distribution charts can be found below:
* The bar in red indicates where Oncodesign Precision Medicine's PS Ratio falls into.
Oncodesign Precision Medicine PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Oncodesign Precision Medicine's Share Price of today is €0.32.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oncodesign Precision Medicine's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Oncodesign Precision Medicine (XPAR:ALOPM) has a PS Ratio of 21.33 as of Jul. 17, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Oncodesign Precision Medicine and its competitors. This is near median its historical median of 20.94. Over the past decade, Oncodesign Precision Medicine's PS Ratio has ranged from 1.11 to 70.73. According to the industry distribution chart, Oncodesign Precision Medicine ranks #641 out of 930 companies in the Biotechnology industry, placing it in the top 68.9%.
Is Oncodesign Precision Medicine's PS Ratio too high?
Oncodesign Precision Medicine's current PS Ratio of 21.33 is near median its 10-year median of 20.94. Over the past 10 years, this metric has ranged from a low of 1.11 to a high of 70.73. The Biotechnology industry median PS Ratio is 9.30. Oncodesign Precision Medicine's value of 21.33 is 129.4% above this industry median. Based on the distribution chart, Oncodesign Precision Medicine ranks #641 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oncodesign Precision Medicine has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oncodesign Precision Medicine's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncodesign Precision Medicine ranks #641 out of 930 companies for PS Ratio. This places Oncodesign Precision Medicine in the lower half of its industry. The industry median PS Ratio is 9.30. Oncodesign Precision Medicine's value of 21.33 is 129.4% above this benchmark. Historically, Oncodesign Precision Medicine's own PS Ratio has ranged from 1.11 to 70.73 over the past decade. While the company's 10-year median is 20.94 vs. the industry median of 9.30, Oncodesign Precision Medicine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.30, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncodesign Precision Medicine's current PS Ratio of 21.33 is 129.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Oncodesign Precision Medicine and its competitors. For the Biotechnology industry, the median PS Ratio is 9.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncodesign Precision Medicine's current PS Ratio is 21.33, which is near median its own 10-year median of 20.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncodesign Precision Medicine stock overvalued right now?
Based on GuruFocus' analysis, Oncodesign Precision Medicine (XPAR:ALOPM) is currently considered Fairly Valued. The stock's GF Value™ is €0.29, compared to a current price of €0.32 — trading 10.3% above its estimated fair value. The current PS Ratio is 21.33, which is near median its 10-year median of 20.94 and 129.4% above the Biotechnology industry median of 9.30. Oncodesign Precision Medicine's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Oncodesign Precision Medicine (XPAR:ALOPM), the current PS Ratio is 21.33 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncodesign Precision Medicine (XPAR:ALOPM) Overvalued in 2026?
Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued.
The current stock price of €0.32 is trading 10.3% above its estimated GF Value™ of €0.29.
GuruFocus considers Oncodesign Precision Medicine to be Fairly Valued.
Key valuation signals for XPAR:ALOPM:
PS Ratio: 21.33 (near median its 10-year median of 20.94)
GF Value™: €0.29 vs. price of €0.32 (10.3% above fair value)
Industry Position: 129.4% above the Biotechnology median (#641 of 930)
No single metric tells the full story. See the XPAR:ALOPM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncodesign Precision Medicine Business Description
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
33GF Score
Get the complete analysis for XPAR:ALOPM
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALOPM has been successfully added to your 
